


## Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride

<b>Cat. No.:</b>	HY-13631F
<b>Molecular Formula:</b>	C <sub>42</sub> H <sub>46</sub> ClFN <sub>8</sub> O <sub>10</sub>
<b>Molecular Weight:</b>	877.31
<b>Target:</b>	Drug-Linker Conjugates for ADC
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related
<b>Storage:</b>	-20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### SOLVENT & SOLUBILITY

#### In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (2.85 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (2.85 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (2.85 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Gly-Gly-Phe-Gly-NH-O-CO-Exatecan, as a drug-linker conjugate composed of linker Gly-Gly-Phe-Gly-NH-O-CO and Exatecan, can be used to prepare antibody conjugate drugs. Exatecan is a DNA topoisomerase I inhibitor that can be used in cancer research<sup>[1][2]</sup>.

### REFERENCES

- [1]. Joto N, et al. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. *Int J Cancer*. 1997;72(4):680-686.
- [2]. Thomas A, et al. Antibody-drug conjugates for cancer therapy. *Lancet Oncol*. 2016;17(6):e254-e262.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA